Method for estimating high sdLDL-C by measuring triglyceride and apolipoprotein B levels

• Published in: Lipids in health and disease Vol. 16; no. 1; p. 21
• Main Authors: Hayashi, Toshiyuki, Koba, Shinji, Ito, Yasuki, Hirano, Tsutomu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 26.01.2017; BioMed Central
• Subjects: Adult; Aged; Analysis; Apolipoprotein B-100 - blood; Apolipoproteins; Biomarkers - blood; Cholesterol, HDL - blood; Cholesterol, LDL; Cholesterol, LDL - blood; Coronary Artery Disease - blood; Diabetes Mellitus, Type 2 - blood; Female; Gel electrophoresis; Humans; Male; Measurement; Methods; Middle Aged; Physiological aspects; Triglycerides - blood; Japan; Apolipoprotein B; Triglycerides; Coronary artery disease; Small dense low-density lipoproteins; Cholesterol
• ISSN: 1476-511X; 1476-511X
• DOI: 10.1186/s12944-017-0417-6

We previously developed an assay to directly measure small dense (sd) low-density lipoprotein cholesterol (LDL-C) levels, which is not widely used in general clinical practice. Therefore, we propose a simpler method, "LDL window," that uses conventional methods for estimating high sdLDL-C levels. We analyzed our previous studies (2006-2008) on healthy subjects and patients with type 2 diabetes and coronary artery disease (CAD). The sdLDL-C level was measured using the precipitation method, and LDL size was determined using gradient gel electrophoresis. The "LDL window" comprises the estimation of LDL particle number and size. We adopted apolipoprotein B (apoB) for the estimation of the LDL particle number and used 110 mg/dL as the cutoff value for hyper-apoB. Triglycerides (TGs) are a powerful inverse determinant of LDL particle size. Therefore, we adopted TG for the estimation of the LDL particle size and used 150 mg/dL as the cutoff value for hyper-TG. Subjects were stratified into the following four subgroups: normal, hyper-TG, hyper-apoB, and hyper-TG/-apoB. Non-high-density lipoprotein cholesterol (non-HDL-C) is a surrogate marker for apoB; therefore, the "alternative LDL window" comprised non-HDL-C (cutoff, 170 mg/dL) and TG. The top quartile (Q4) of sdLDL-C (>31 mg/dL) doubled in patients with diabetes and CAD. The hyper-TG/-apoB group in the "LDL window" represented >90% Q4 and <4% Q1 and Q2, irrespective of the subjects. The sdLDL-C levels in the hyper-TG/-apoB group were 50% higher in patients with diabetes and CAD than those in controls. Similar results were obtained using the "alternative LDL window." Our proposed "LDL window" may help identify patients at high risk of CAD independent of LDL-C.